ClinicalTrials.gg
TerminatedNCT04258020Updated Jan 13, 2022Results posted

Postextubation Management in Patients at Risk for Extubation Failure

An interventional study of BiPAP and HFNC in Ventilatory Failure, sponsored by OhioHealth. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-13.

Sponsored by OhioHealth · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Significant impact of COVID pandemic on ability to conduct study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Hypoventilation with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hypoventilation · United States.

Enrollment
17th of 20
6 · median 62
Started
2020
with 4 others
No phase
19 of 27
none open now
Registered
15th of 27
by date

Among the 27 studies in Hypoventilation with a site in United States, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2020, is one of 19 with no phase, and was the 15th registered.

Hypoventilation

96 studies on the registry are indexed under Hypoventilation; 21 are open to participants now.

Browse Hypoventilation studies →

Open to participants now

3 of the 27 studies in Hypoventilation with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Hypoventilation studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hypoventilation with a site in United States, or all of them as a file.
02

Study summary

At the time of weaning from mechanical ventilation, patients with heart and/or lung conditions will be given oxygen support with alternating bilevel positive airway pressure (BiPAP; oxygen via face mask) and heated high flow nasal cannula oxygen (HFNC; oxygen via nasal cannula) to see if this method reduces the likelihood of re-intubation.

Read the detailed description

It is clinically challenging to predict when patients can be successfully removed from mechanical ventilation (MV). Liberating high-risk patients such as the elderly and those with complex, chronic cardiac or pulmonary diseases from MV is particularly challenging.

Evidence from randomized trials and meta-analyses suggests that the type of postextubation supportive care provided, such as oxygen delivery via nose or mouth, may affect the risk of reintubation. However, it is unclear which of many possible postextubation management protocols results in the best patient outcomes, particularly for this subset of high-risk patients.

The purpose of this study is therefore to assess a standardized combined protocol of postextubation oxygen delivery consisting of early, alternating BiPAP with HFNC over 24 hours following extubation. BiPAP and HFNC are both currently provided to patients as standard of care, based on clinician judgement; however, the timing and nature of the methods are variable.

03

Conditions studied

  • Ventilatory Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented high-risk factors of interest [congestive heart failure (CHF), (COPD), and/or positive fluid balance]
  • The modified rapid shallow breathing index on day of extubation must be between 58-105 breaths per minute per liter (breaths/min/L)
  • Patient must successfully complete spontaneous breathing trial and be determined eligible for extubation
  • Only primary extubations will be included

Exclusion criteria

Exclusion Criteria:

  • Undergoing terminal extubation or placed on comfort care
  • Home ventilator use
  • Any that would preclude the postextubation protocol (e.g., facial trauma, tracheotomy, or any other reason that would preclude use of BiPAP or HFNC)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Experimental: alternating BiPAP and HFNC

    Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation

    Device: BiPAP · Device: HFNC

  • No intervention
    Historical Control: standard of care

    A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.

Interventions

  • DeviceBiPAP

    Bilevel Positive Airway Pressure (BiPAP) oxygen administration

  • DeviceHFNC

    Heated High Flow Nasal Cannula oxygen administration

06

What researchers measure

Primary outcomes

  1. Re-intubation Within 72 Hours

    The number of patients who require re-intubation

    Time frame: 72 hours following extubation

Secondary outcomes

  1. Re-intubation Within 1 Week

    The number of patients who require re-intubation

    Time frame: 1 week following extubation

  2. Length of Stay

    Hospital length of stay

    Time frame: Through hospital discharge, an average of 10.9 ± 1.91 days

  3. Ventilator Time

    The total duration of time patients spend on a ventilator

    Time frame: Through hospital discharge, an average of 10.9 ± 1.91 days

  4. Mortality

    The proportion of patients who expire during the hospital stay

    Time frame: Through hospital discharge, an average of 10.9 ± 1.91 days

  5. Adverse Event Rate

    The proportion of patients experiencing an adverse event

    Time frame: Through 1 week following extubation

  6. 30-day Readmission

    The proportion of patients who require re-admission within 30 days of discharge

    Time frame: 30 days following discharge

07

Results

Posted Jan 13, 2022

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Started40
Completed30
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryRe-intubation Within 72 Hours

The number of patients who require re-intubation

Time frame:
72 hours following extubation
Reported as:
Number · participants
Re-intubation Within 72 Hours
participantsExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Re-intubation Within 72 Hours0—
SecondaryRe-intubation Within 1 Week

The number of patients who require re-intubation

Time frame:
1 week following extubation
Reported as:
Number · participants
Re-intubation Within 1 Week
participantsExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Re-intubation Within 1 Week0—
SecondaryLength of Stay

Hospital length of stay

Time frame:
Through hospital discharge, an average of 10.9 ± 1.91 days
Reported as:
Mean · Days
Length of Stay
DaysExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Length of Stay10.9 ± 1.91—
SecondaryVentilator Time

The total duration of time patients spend on a ventilator

Time frame:
Through hospital discharge, an average of 10.9 ± 1.91 days
Reported as:
Mean · Days
Ventilator Time
DaysExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Ventilator Time3.5 ± 1.33—
SecondaryMortality

The proportion of patients who expire during the hospital stay

Time frame:
Through hospital discharge, an average of 10.9 ± 1.91 days
Reported as:
Count of participants · Participants
Mortality
ParticipantsExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Mortality0—
SecondaryAdverse Event Rate

The proportion of patients experiencing an adverse event

Time frame:
Through 1 week following extubation
Reported as:
Count of participants · Participants
Adverse Event Rate
ParticipantsExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
Adverse Event Rate1—
Secondary30-day Readmission

The proportion of patients who require re-admission within 30 days of discharge

Time frame:
30 days following discharge
Reported as:
Count of participants · Participants
30-day Readmission
ParticipantsExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
30-day Readmission0—

Adverse events

Collected over Through hospital discharge, and average of 10.9 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Alternating BiPAP and HFNC0/3 (0%)0/3 (0%)1/3 (33.3%)
Historical Control: Standard of Care———
Most frequent other events
Most frequent other events
EventExperimental: Alternating BiPAP and HFNCHistorical Control: Standard of Care
VomitingGastrointestinal disorders1/3—

Baseline characteristics

Because the prospective group was terminated, no data collection for the historical control was collected.

Age, Categorical
Age, Categorical(Participants)Experimental: Alternating BiPAP and HFNCHistorical Control: Standard of CareTotal
<=18 years0—0
Between 18 and 65 years1—1
>=65 years2—2
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Alternating BiPAP and HFNCHistorical Control: Standard of CareTotal
Female2—2
Male1—1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Alternating BiPAP and HFNCHistorical Control: Standard of CareTotal
American Indian or Alaska Native0—0
Asian0—0
Native Hawaiian or Other Pacific Islander0—0
Black or African American1—1
White2—2
More than one race0—0
Unknown or Not Reported0—0
Region of Enrollment
Region of Enrollment(participants)Experimental: Alternating BiPAP and HFNCHistorical Control: Standard of CareTotal
United States3—3
08

Study locations

1 site
  • OhioHealth Grant Medical Center
    Columbus, Ohio 43215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Feb 2020, 0 months.

Results were first posted in Jan 2022, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Feb 6, 2020
StartActual
Feb 11, 2020
Primary completionActual
Feb 25, 2020
CompletionActual
Apr 2, 2020
Results first posted
Jan 13, 2022
Last update
Jan 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04258020
Lead sponsor
OhioHealth
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Feb 11, 2020
Primary completion
Feb 25, 2020
Completion
Apr 2, 2020
Results posted
Jan 13, 2022
Last update
Jan 13, 2022

Study contacts

Kiran Devulapally, MD
principal investigator · OhioHealth

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion